Ligand source activities (1 row/activity)



Get vendors


Ligands (move mouse cursor over ligand name to see structure) Receptor Activity Chemical information
Sel. page Common
name		 GPCRdb
ID		 Reference
ligand		 Vendors

 Species

 Assay
Type

 Activity
Type		 Activity
Relation		 Activity
Value		 p-value
(-log)		 Fold
selectivity		 Tested
GPCRs		 Assay
Description		 Source

 Mol
weight		 Rot
Bonds		 H don

 H acc

 LogP

 Smiles

 DOI
3930 2151 None 37 Human Functional pEC50 = 5.9 5.9 -28 3
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.6019/CHEMBL5442687
540335 2151 None 37 Human Functional pEC50 = 5.9 5.9 -28 3
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.6019/CHEMBL5442687
CHEMBL106525 2151 None 37 Human Functional pEC50 = 5.9 5.9 -28 3
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.6019/CHEMBL5442687
104943 55402 None 31 Human Functional pIC50 = 6.0 6.0 -2344 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 412 7 1 3 5.1 COc1ccccc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1 10.6019/CHEMBL5442687
CHEMBL16192 55402 None 31 Human Functional pIC50 = 6.0 6.0 -2344 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 412 7 1 3 5.1 COc1ccccc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1 10.6019/CHEMBL5442687
6603703 208 None 8 Human Functional pIC50 = 5.8 5.8 -478 18
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 329 2 3 4 3.3 NC[C@@H]1O[C@@H](Cc2c1ccc(c2O)O)C12CC3CC(C2)CC(C1)C3 10.6019/CHEMBL5442687
9637 208 None 8 Human Functional pIC50 = 5.8 5.8 -478 18
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 329 2 3 4 3.3 NC[C@@H]1O[C@@H](Cc2c1ccc(c2O)O)C12CC3CC(C2)CC(C1)C3 10.6019/CHEMBL5442687
CHEMBL291143 208 None 8 Human Functional pIC50 = 5.8 5.8 -478 18
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 329 2 3 4 3.3 NC[C@@H]1O[C@@H](Cc2c1ccc(c2O)O)C12CC3CC(C2)CC(C1)C3 10.6019/CHEMBL5442687
135413536 448 None 58 Human Functional pIC50 = 5.7 5.7 -7943 7
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 534 6 2 5 5.0 Fc1ccc(cc1)[C@H]1[C@H](OCCN1Cc1[nH][nH]c(=O)n1)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C 10.6019/CHEMBL5442687
230 448 None 58 Human Functional pIC50 = 5.7 5.7 -7943 7
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 534 6 2 5 5.0 Fc1ccc(cc1)[C@H]1[C@H](OCCN1Cc1[nH][nH]c(=O)n1)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C 10.6019/CHEMBL5442687
3490 448 None 58 Human Functional pIC50 = 5.7 5.7 -7943 7
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 534 6 2 5 5.0 Fc1ccc(cc1)[C@H]1[C@H](OCCN1Cc1[nH][nH]c(=O)n1)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C 10.6019/CHEMBL5442687
6918365 448 None 58 Human Functional pIC50 = 5.7 5.7 -7943 7
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 534 6 2 5 5.0 Fc1ccc(cc1)[C@H]1[C@H](OCCN1Cc1[nH][nH]c(=O)n1)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C 10.6019/CHEMBL5442687
CHEMBL1471 448 None 58 Human Functional pIC50 = 5.7 5.7 -7943 7
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 534 6 2 5 5.0 Fc1ccc(cc1)[C@H]1[C@H](OCCN1Cc1[nH][nH]c(=O)n1)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C 10.6019/CHEMBL5442687
DB00673 448 None 58 Human Functional pIC50 = 5.7 5.7 -7943 7
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 534 6 2 5 5.0 Fc1ccc(cc1)[C@H]1[C@H](OCCN1Cc1[nH][nH]c(=O)n1)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C 10.6019/CHEMBL5442687
158797 3771 None 19 Human Functional pIC50 = 5.7 5.7 -12 2
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 303 7 1 2 4.6 COc1cccc(c1)[C@H](NCCCc1ccccc1Cl)C 10.6019/CHEMBL5442687
718 3771 None 19 Human Functional pIC50 = 5.7 5.7 -12 2
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 303 7 1 2 4.6 COc1cccc(c1)[C@H](NCCCc1ccccc1Cl)C 10.6019/CHEMBL5442687
CHEMBL292376 3771 None 19 Human Functional pIC50 = 5.7 5.7 -12 2
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 303 7 1 2 4.6 COc1cccc(c1)[C@H](NCCCc1ccccc1Cl)C 10.6019/CHEMBL5442687
621 3035 None 27 Human Functional pIC50 = 5.7 5.7 -6309 6
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 554 9 4 5 5.6 O=C(N[C@](C(=O)NCC1(CCCCC1)c1ccccn1)(Cc1c[nH]c2c1cccc2)C)Nc1ccc(cc1)[N+](=O)[O-] 10.6019/CHEMBL5442687
9937534 3035 None 27 Human Functional pIC50 = 5.7 5.7 -6309 6
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 554 9 4 5 5.6 O=C(N[C@](C(=O)NCC1(CCCCC1)c1ccccn1)(Cc1c[nH]c2c1cccc2)C)Nc1ccc(cc1)[N+](=O)[O-] 10.6019/CHEMBL5442687
CHEMBL329650 3035 None 27 Human Functional pIC50 = 5.7 5.7 -6309 6
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 554 9 4 5 5.6 O=C(N[C@](C(=O)NCC1(CCCCC1)c1ccccn1)(Cc1c[nH]c2c1cccc2)C)Nc1ccc(cc1)[N+](=O)[O-] 10.6019/CHEMBL5442687
4534 192011 None 61 Human Functional pIC50 = 5.6 5.6 -27 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 302 5 4 4 3.6 CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1 10.6019/CHEMBL5442687
CHEMBL52 192011 None 61 Human Functional pIC50 = 5.6 5.6 -27 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 302 5 4 4 3.6 CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1 10.6019/CHEMBL5442687
512282 758 None 42 Human Functional pIC50 = 5.6 5.6 -354 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 434 6 2 4 3.1 NC(=O)Nc1cc(Cl)ccc1OCC(=O)N1CCN(C[C@H]1C)Cc1ccc(cc1)F 10.6019/CHEMBL5442687
767 758 None 42 Human Functional pIC50 = 5.6 5.6 -354 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 434 6 2 4 3.1 NC(=O)Nc1cc(Cl)ccc1OCC(=O)N1CCN(C[C@H]1C)Cc1ccc(cc1)F 10.6019/CHEMBL5442687
CHEMBL232656 758 None 42 Human Functional pIC50 = 5.6 5.6 -354 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 434 6 2 4 3.1 NC(=O)Nc1cc(Cl)ccc1OCC(=O)N1CCN(C[C@H]1C)Cc1ccc(cc1)F 10.6019/CHEMBL5442687
9893924 4750 None 24 Human Functional pIC50 = 5.6 5.6 -89 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 554 11 3 4 5.4 S=C(NCCCc1c[nH]cn1)NCCCN(Cc1ccc(Cl)c(Cl)c1)c1ccc(Br)cn1 10.6019/CHEMBL5442687
CHEMBL103769 4750 None 24 Human Functional pIC50 = 5.6 5.6 -89 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 554 11 3 4 5.4 S=C(NCCCc1c[nH]cn1)NCCCN(Cc1ccc(Cl)c(Cl)c1)c1ccc(Br)cn1 10.6019/CHEMBL5442687
2202 2761 None 30 Human Functional pIC50 = 5.6 5.6 - 1
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 629 8 1 9 2.9 COc1cc(OC)ccc1S(=O)(=O)N1c2ccc(cc2[C@@](C1=O)(N1C[C@@H](C[C@H]1C(=O)N(C)C)O)c1ccccc1OC)Cl 10.6019/CHEMBL5442687
9895468 2761 None 30 Human Functional pIC50 = 5.6 5.6 - 1
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 629 8 1 9 2.9 COc1cc(OC)ccc1S(=O)(=O)N1c2ccc(cc2[C@@](C1=O)(N1C[C@@H](C[C@H]1C(=O)N(C)C)O)c1ccccc1OC)Cl 10.6019/CHEMBL5442687
CHEMBL582857 2761 None 30 Human Functional pIC50 = 5.6 5.6 - 1
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 629 8 1 9 2.9 COc1cc(OC)ccc1S(=O)(=O)N1c2ccc(cc2[C@@](C1=O)(N1C[C@@H](C[C@H]1C(=O)N(C)C)O)c1ccccc1OC)Cl 10.6019/CHEMBL5442687
DB12643 2761 None 30 Human Functional pIC50 = 5.6 5.6 - 1
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 629 8 1 9 2.9 COc1cc(OC)ccc1S(=O)(=O)N1c2ccc(cc2[C@@](C1=O)(N1C[C@@H](C[C@H]1C(=O)N(C)C)O)c1ccccc1OC)Cl 10.6019/CHEMBL5442687
2419 3463 None 53 Human Functional pIC50 = 5.6 5.6 -4365 19
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 415 16 4 5 4.1 OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O 10.6019/CHEMBL5442687
5152 3463 None 53 Human Functional pIC50 = 5.6 5.6 -4365 19
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 415 16 4 5 4.1 OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O 10.6019/CHEMBL5442687
5152.0 3463 None 53 Human Functional pIC50 = 5.6 5.6 -4365 19
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 415 16 4 5 4.1 OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O 10.6019/CHEMBL5442687
559 3463 None 53 Human Functional pIC50 = 5.6 5.6 -4365 19
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 415 16 4 5 4.1 OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O 10.6019/CHEMBL5442687
CHEMBL1263 3463 None 53 Human Functional pIC50 = 5.6 5.6 -4365 19
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 415 16 4 5 4.1 OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O 10.6019/CHEMBL5442687
DB00938 3463 None 53 Human Functional pIC50 = 5.6 5.6 -4365 19
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 415 16 4 5 4.1 OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O 10.6019/CHEMBL5442687
1209 1658 None 52 Human Functional pIC50 = 5.6 5.6 -21 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 309 6 1 2 4.4 CNCCC(c1ccccc1)Oc1ccc(cc1)C(F)(F)F 10.6019/CHEMBL5442687
203 1658 None 52 Human Functional pIC50 = 5.6 5.6 -21 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 309 6 1 2 4.4 CNCCC(c1ccccc1)Oc1ccc(cc1)C(F)(F)F 10.6019/CHEMBL5442687
3386 1658 None 52 Human Functional pIC50 = 5.6 5.6 -21 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 309 6 1 2 4.4 CNCCC(c1ccccc1)Oc1ccc(cc1)C(F)(F)F 10.6019/CHEMBL5442687
CHEMBL41 1658 None 52 Human Functional pIC50 = 5.6 5.6 -21 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 309 6 1 2 4.4 CNCCC(c1ccccc1)Oc1ccc(cc1)C(F)(F)F 10.6019/CHEMBL5442687
DB00472 1658 None 52 Human Functional pIC50 = 5.6 5.6 -21 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 309 6 1 2 4.4 CNCCC(c1ccccc1)Oc1ccc(cc1)C(F)(F)F 10.6019/CHEMBL5442687
9893924 4750 None 24 Human Functional pIC50 = 5.6 5.6 -89 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 554 11 3 4 5.4 S=C(NCCCc1c[nH]cn1)NCCCN(Cc1ccc(Cl)c(Cl)c1)c1ccc(Br)cn1 10.6019/CHEMBL5442687
CHEMBL103769 4750 None 24 Human Functional pIC50 = 5.6 5.6 -89 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 554 11 3 4 5.4 S=C(NCCCc1c[nH]cn1)NCCCN(Cc1ccc(Cl)c(Cl)c1)c1ccc(Br)cn1 10.6019/CHEMBL5442687
52936725 61270 None 22 Human Functional pIC50 = 5.5 5.5 -602 10
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 432 6 2 4 6.3 Cc1cc(C)cc(-c2cnc3cc(Cl)c(-c4cccc(O)c4)cc3c2OCCCN)c1 10.6019/CHEMBL5442687
CHEMBL1766103 61270 None 22 Human Functional pIC50 = 5.5 5.5 -602 10
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 432 6 2 4 6.3 Cc1cc(C)cc(-c2cnc3cc(Cl)c(-c4cccc(O)c4)cc3c2OCCCN)c1 10.6019/CHEMBL5442687
10150497 4074 None 40 Human Functional pIC50 = 5.5 5.5 -457 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 380 4 1 7 2.7 NCCc1cn(c2c1cccc2)S(=O)(=O)c1c(Cl)nc2n1ccs2 10.6019/CHEMBL5442687
3240 4074 None 40 Human Functional pIC50 = 5.5 5.5 -457 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 380 4 1 7 2.7 NCCc1cn(c2c1cccc2)S(=O)(=O)c1c(Cl)nc2n1ccs2 10.6019/CHEMBL5442687
CHEMBL392760 4074 None 40 Human Functional pIC50 = 5.5 5.5 -457 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 380 4 1 7 2.7 NCCc1cn(c2c1cccc2)S(=O)(=O)c1c(Cl)nc2n1ccs2 10.6019/CHEMBL5442687
156419 938 None 48 Human Functional pIC50 = 5.5 5.5 -70 20
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442687
156419.0 938 None 48 Human Functional pIC50 = 5.5 5.5 -70 20
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442687
3308 938 None 48 Human Functional pIC50 = 5.5 5.5 -70 20
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442687
647 938 None 48 Human Functional pIC50 = 5.5 5.5 -70 20
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442687
CHEMBL1201284 938 None 48 Human Functional pIC50 = 5.5 5.5 -70 20
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442687
DB01012 938 None 48 Human Functional pIC50 = 5.5 5.5 -70 20
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442687
487 3634 None 20 Human Functional pIC50 = 5.5 5.5 -1 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.6019/CHEMBL5442687
60602 3634 None 20 Human Functional pIC50 = 5.5 5.5 -1 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.6019/CHEMBL5442687
CHEMBL405355 3634 None 20 Human Functional pIC50 = 5.5 5.5 -1 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.6019/CHEMBL5442687
DB09239 3634 None 20 Human Functional pIC50 = 5.5 5.5 -1 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.6019/CHEMBL5442687
456214 87380 None 43 Human Functional pIC50 = 5.5 5.5 -263 6
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 388 7 3 7 4.2 CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1 10.6019/CHEMBL5442687
CHEMBL23327 87380 None 43 Human Functional pIC50 = 5.5 5.5 -263 6
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 388 7 3 7 4.2 CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1 10.6019/CHEMBL5442687
5311122 4068 None 4 Human Functional pIC50 = 5.5 5.5 -288 4
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 456 7 0 3 6.5 COc1ccc2c(c1)C(CCC2)C(=O)N(c1ccc(cc1)C(C)C)Cc1ccc(cc1)N(C)C 10.6019/CHEMBL5442687
581 4068 None 4 Human Functional pIC50 = 5.5 5.5 -288 4
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 456 7 0 3 6.5 COc1ccc2c(c1)C(CCC2)C(=O)N(c1ccc(cc1)C(C)C)Cc1ccc(cc1)N(C)C 10.6019/CHEMBL5442687
CHEMBL1628668 4068 None 4 Human Functional pIC50 = 5.5 5.5 -288 4
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 456 7 0 3 6.5 COc1ccc2c(c1)C(CCC2)C(=O)N(c1ccc(cc1)C(C)C)Cc1ccc(cc1)N(C)C 10.6019/CHEMBL5442687
1890 2759 None 31 Human Functional pIC50 = 5.5 5.5 -26 28
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442687
4449 2759 None 31 Human Functional pIC50 = 5.5 5.5 -26 28
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442687
7247 2759 None 31 Human Functional pIC50 = 5.5 5.5 -26 28
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442687
CHEMBL623 2759 None 31 Human Functional pIC50 = 5.5 5.5 -26 28
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442687
DB01149 2759 None 31 Human Functional pIC50 = 5.5 5.5 -26 28
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442687
1692 2154 None 25 Human Functional pIC50 = 5.5 5.5 -114 18
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 411 6 2 4 5.5 CCc1ccc(cc1)OCc1ccccc1C(=O)Nc1ccc2c(c1)c(N)cc(n2)C 10.6019/CHEMBL5442687
5311340 2154 None 25 Human Functional pIC50 = 5.5 5.5 -114 18
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 411 6 2 4 5.5 CCc1ccc(cc1)OCc1ccccc1C(=O)Nc1ccc2c(c1)c(N)cc(n2)C 10.6019/CHEMBL5442687
CHEMBL140979 2154 None 25 Human Functional pIC50 = 5.5 5.5 -114 18
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 411 6 2 4 5.5 CCc1ccc(cc1)OCc1ccccc1C(=O)Nc1ccc2c(c1)c(N)cc(n2)C 10.6019/CHEMBL5442687
10071196 3124 None 53 Human Functional pIC50 = 5.5 5.5 -239 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 427 8 1 3 4.7 CC(COc1ccc(cc1)CNC(=O)N(C1CCN(CC1)C)Cc1ccc(cc1)F)C 10.6019/CHEMBL5442687
10071196.0 3124 None 53 Human Functional pIC50 = 5.5 5.5 -239 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 427 8 1 3 4.7 CC(COc1ccc(cc1)CNC(=O)N(C1CCN(CC1)C)Cc1ccc(cc1)F)C 10.6019/CHEMBL5442687
5142 3124 None 53 Human Functional pIC50 = 5.5 5.5 -239 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 427 8 1 3 4.7 CC(COc1ccc(cc1)CNC(=O)N(C1CCN(CC1)C)Cc1ccc(cc1)F)C 10.6019/CHEMBL5442687
8423 3124 None 53 Human Functional pIC50 = 5.5 5.5 -239 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 427 8 1 3 4.7 CC(COc1ccc(cc1)CNC(=O)N(C1CCN(CC1)C)Cc1ccc(cc1)F)C 10.6019/CHEMBL5442687
CHEMBL2111101 3124 None 53 Human Functional pIC50 = 5.5 5.5 -239 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 427 8 1 3 4.7 CC(COc1ccc(cc1)CNC(=O)N(C1CCN(CC1)C)Cc1ccc(cc1)F)C 10.6019/CHEMBL5442687
DB05316 3124 None 53 Human Functional pIC50 = 5.5 5.5 -239 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 427 8 1 3 4.7 CC(COc1ccc(cc1)CNC(=O)N(C1CCN(CC1)C)Cc1ccc(cc1)F)C 10.6019/CHEMBL5442687
25150014 3885 None 44 Human Functional pIC50 = 6.4 6.4 -9 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 264 3 1 1 3.4 OC(=O)CCc1ccc(cc1)C#Cc1ccccc1C 10.6019/CHEMBL5442687
3952 3885 None 44 Human Functional pIC50 = 6.4 6.4 -9 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 264 3 1 1 3.4 OC(=O)CCc1ccc(cc1)C#Cc1ccccc1C 10.6019/CHEMBL5442687
CHEMBL449588 3885 None 44 Human Functional pIC50 = 6.4 6.4 -9 9
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 264 3 1 1 3.4 OC(=O)CCc1ccc(cc1)C#Cc1ccccc1C 10.6019/CHEMBL5442687
662 3680 None 7 Human Functional pIC50 = 5.4 5.4 -1 12
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 756 14 2 8 6.3 COc1ccc2c(c1)ccc(c2)S(=O)(=O)N[C@@H](c1ccc2c(c1)OCO2)CC(=O)N[C@@H](C(=O)N(C(C)C)C)Cc1ccc(cc1)CN1[C@H](C)CCC[C@@H]1C 10.6019/CHEMBL5442687
9853583 3680 None 7 Human Functional pIC50 = 5.4 5.4 -1 12
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 756 14 2 8 6.3 COc1ccc2c(c1)ccc(c2)S(=O)(=O)N[C@@H](c1ccc2c(c1)OCO2)CC(=O)N[C@@H](C(=O)N(C(C)C)C)Cc1ccc(cc1)CN1[C@H](C)CCC[C@@H]1C 10.6019/CHEMBL5442687
CHEMBL2021721 3680 None 7 Human Functional pIC50 = 5.4 5.4 -1 12
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 756 14 2 8 6.3 COc1ccc2c(c1)ccc(c2)S(=O)(=O)N[C@@H](c1ccc2c(c1)OCO2)CC(=O)N[C@@H](C(=O)N(C(C)C)C)Cc1ccc(cc1)CN1[C@H](C)CCC[C@@H]1C 10.6019/CHEMBL5442687
28 3496 None 35 Human Functional pIC50 = 5.4 5.4 -1 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 486 9 1 7 5.2 COc1ccc(cc1OCCN(C)C)NC(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C 10.6019/CHEMBL5442687
3292447 3496 None 35 Human Functional pIC50 = 5.4 5.4 -1 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 486 9 1 7 5.2 COc1ccc(cc1OCCN(C)C)NC(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C 10.6019/CHEMBL5442687
CHEMBL20963 3496 None 35 Human Functional pIC50 = 5.4 5.4 -1 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 486 9 1 7 5.2 COc1ccc(cc1OCCN(C)C)NC(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C 10.6019/CHEMBL5442687
209 3057 None 57 Human Functional pIC50 = 5.4 5.4 -1737 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.6019/CHEMBL5442687
2113 3057 None 57 Human Functional pIC50 = 5.4 5.4 -1737 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.6019/CHEMBL5442687
4748 3057 None 57 Human Functional pIC50 = 5.4 5.4 -1737 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.6019/CHEMBL5442687
4748.0 3057 None 57 Human Functional pIC50 = 5.4 5.4 -1737 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.6019/CHEMBL5442687
CHEMBL567 3057 None 57 Human Functional pIC50 = 5.4 5.4 -1737 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.6019/CHEMBL5442687
DB00850 3057 None 57 Human Functional pIC50 = 5.4 5.4 -1737 25
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.6019/CHEMBL5442687
11224758 2353 None 4 Human Functional pIC50 = 5.4 5.4 -16 4
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 451 9 1 4 5.3 CSc1ccccc1N1CCN(CC1)CCCCCC(=O)NC1CCCc2c1cccc2 10.6019/CHEMBL5442687
8435 2353 None 4 Human Functional pIC50 = 5.4 5.4 -16 4
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 451 9 1 4 5.3 CSc1ccccc1N1CCN(CC1)CCCCCC(=O)NC1CCCc2c1cccc2 10.6019/CHEMBL5442687
CHEMBL225284 2353 None 4 Human Functional pIC50 = 5.4 5.4 -16 4
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 451 9 1 4 5.3 CSc1ccccc1N1CCN(CC1)CCCCCC(=O)NC1CCCc2c1cccc2 10.6019/CHEMBL5442687
188 3391 None 49 Human Functional pIC50 = 5.4 5.4 -1122 2
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 281 2 1 3 4.1 Nc1nc(cc(n1)c1ccc(c2c1cccc2)F)C(C)C 10.6019/CHEMBL5442687
196968 3391 None 49 Human Functional pIC50 = 5.4 5.4 -1122 2
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 281 2 1 3 4.1 Nc1nc(cc(n1)c1ccc(c2c1cccc2)F)C(C)C 10.6019/CHEMBL5442687
CHEMBL473186 3391 None 49 Human Functional pIC50 = 5.4 5.4 -1122 2
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 281 2 1 3 4.1 Nc1nc(cc(n1)c1ccc(c2c1cccc2)F)C(C)C 10.6019/CHEMBL5442687
276 3513 None 37 Human Functional pIC50 = 5.4 5.4 -2041 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 451 5 2 6 4.1 COc1ccc(cc1N1CCNCC1)NS(=O)(=O)c1sc2c(c1C)cc(cc2)Cl 10.6019/CHEMBL5442687
5312149 3513 None 37 Human Functional pIC50 = 5.4 5.4 -2041 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 451 5 2 6 4.1 COc1ccc(cc1N1CCNCC1)NS(=O)(=O)c1sc2c(c1C)cc(cc2)Cl 10.6019/CHEMBL5442687
CHEMBL431298 3513 None 37 Human Functional pIC50 = 5.4 5.4 -2041 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 451 5 2 6 4.1 COc1ccc(cc1N1CCNCC1)NS(=O)(=O)c1sc2c(c1C)cc(cc2)Cl 10.6019/CHEMBL5442687
130 3500 None 32 Human Functional pIC50 = 5.4 5.4 -2041 10
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 520 3 0 6 5.6 CN1CCC2(CC1)COc1c2cc2c(c1)CCN2C(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C 10.6019/CHEMBL5442687
3378093 3500 None 32 Human Functional pIC50 = 5.4 5.4 -2041 10
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 520 3 0 6 5.6 CN1CCC2(CC1)COc1c2cc2c(c1)CCN2C(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C 10.6019/CHEMBL5442687
CHEMBL281350 3500 None 32 Human Functional pIC50 = 5.4 5.4 -2041 10
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 520 3 0 6 5.6 CN1CCC2(CC1)COc1c2cc2c(c1)CCN2C(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C 10.6019/CHEMBL5442687
1969 811 None 43 Human Functional pIC50 = 5.3 5.3 -1905 3
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 309 5 2 4 3.4 CC(Oc1ccc(cc1)Cc1ccc(cc1)NC1=NCCN1)C 10.6019/CHEMBL5442687
9839644 811 None 43 Human Functional pIC50 = 5.3 5.3 -1905 3
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 309 5 2 4 3.4 CC(Oc1ccc(cc1)Cc1ccc(cc1)NC1=NCCN1)C 10.6019/CHEMBL5442687
CHEMBL9540 811 None 43 Human Functional pIC50 = 5.3 5.3 -1905 3
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 309 5 2 4 3.4 CC(Oc1ccc(cc1)Cc1ccc(cc1)NC1=NCCN1)C 10.6019/CHEMBL5442687
44634573 2748 None 1 Human Functional pIC50 = 5.3 5.3 -575 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 465 6 0 2 5.0 Cc1n(C/C=C/c2ccccc2)c2[n+](c1P(=S)(c1ccccc1)c1ccccc1)cccc2 10.6019/CHEMBL5442687
9168 2748 None 1 Human Functional pIC50 = 5.3 5.3 -575 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 465 6 0 2 5.0 Cc1n(C/C=C/c2ccccc2)c2[n+](c1P(=S)(c1ccccc1)c1ccccc1)cccc2 10.6019/CHEMBL5442687
CHEMBL1474387 2748 None 1 Human Functional pIC50 = 5.3 5.3 -575 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 465 6 0 2 5.0 Cc1n(C/C=C/c2ccccc2)c2[n+](c1P(=S)(c1ccccc1)c1ccccc1)cccc2 10.6019/CHEMBL5442687
CHEMBL1622930 2748 None 1 Human Functional pIC50 = 5.3 5.3 -575 15
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 465 6 0 2 5.0 Cc1n(C/C=C/c2ccccc2)c2[n+](c1P(=S)(c1ccccc1)c1ccccc1)cccc2 10.6019/CHEMBL5442687
164548564 195175 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 367 1 1 4 3.3 O=C(Nc1ncc(C(F)(F)F)cn1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5398106 195175 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 367 1 1 4 3.3 O=C(Nc1ncc(C(F)(F)F)cn1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548692 195284 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 391 1 1 4 3.8 N#Cc1ccc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)nc1C(F)(F)F nan
CHEMBL5400100 195284 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 391 1 1 4 3.8 N#Cc1ccc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)nc1C(F)(F)F nan
164548590 195291 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 383 1 1 4 3.8 O=C(Nc1cc(Cl)c(C(F)(F)F)cn1)N1C2CCC1c1cncnc1C2 nan
CHEMBL5400228 195291 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 383 1 1 4 3.8 O=C(Nc1cc(Cl)c(C(F)(F)F)cn1)N1C2CCC1c1cncnc1C2 nan
164548613 195363 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 364 3 1 4 3.5 O=C(Nc1ccc(OC(F)F)cn1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5402018 195363 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 364 3 1 4 3.5 O=C(Nc1ccc(OC(F)F)cn1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548643 195421 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 365 2 1 5 3.6 O=C(Nc1nc(-c2ccccc2)no1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5403385 195421 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 365 2 1 5 3.6 O=C(Nc1nc(-c2ccccc2)no1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548706 195473 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 382 1 2 3 3.2 O=C(Nc1cc(C(F)(F)F)ncc1F)N1[C@H]2CC[C@@H]1c1c[nH]c(=O)cc1C2 nan
CHEMBL5404390 195473 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 382 1 2 3 3.2 O=C(Nc1cc(C(F)(F)F)ncc1F)N1[C@H]2CC[C@@H]1c1c[nH]c(=O)cc1C2 nan
164548701 195557 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 333 2 1 5 2.9 CCc1nnc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)s1 nan
CHEMBL5406035 195557 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 333 2 1 5 2.9 CCc1nnc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)s1 nan
164548640 195577 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 382 2 1 6 3.4 O=C(Nc1nnc(-c2ccncc2)s1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5406392 195577 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 382 2 1 6 3.4 O=C(Nc1nnc(-c2ccncc2)s1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548747 195635 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 365 2 1 5 3.6 O=C(Nc1nnc(-c2ccccc2)o1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5407784 195635 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 365 2 1 5 3.6 O=C(Nc1nnc(-c2ccccc2)o1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548631 195917 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 323 1 1 4 2.8 N#Cc1ccc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)nc1 nan
CHEMBL5413335 195917 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 323 1 1 4 2.8 N#Cc1ccc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)nc1 nan
164548705 196157 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 366 1 1 3 4.2 O=C(Nc1ccc(Cl)c(Cl)n1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5417806 196157 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 366 1 1 3 4.2 O=C(Nc1ccc(Cl)c(Cl)n1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548600 196293 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 390 3 1 4 4.7 O=C(Nc1ccc(Oc2ccccc2)nc1)N1C2CCC1c1ccnc(F)c1C2 nan
CHEMBL5420624 196293 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 390 3 1 4 4.7 O=C(Nc1ccc(Oc2ccccc2)nc1)N1C2CCC1c1ccnc(F)c1C2 nan
164548622 196338 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 384 1 1 3 4.4 O=C(Nc1nc(Cl)c(Cl)cc1F)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5421727 196338 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 384 1 1 3 4.4 O=C(Nc1nc(Cl)c(Cl)cc1F)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548719 196382 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 350 1 1 3 3.7 O=C(Nc1cnc(Cl)cc1F)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5422604 196382 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 350 1 1 3 3.7 O=C(Nc1cnc(Cl)cc1F)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548625 196477 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 384 1 1 3 4.1 O=C(Nc1cc(C(F)(F)F)ncc1F)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5424723 196477 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 384 1 1 3 4.1 O=C(Nc1cc(C(F)(F)F)ncc1F)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548565 196602 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 366 1 1 3 4.2 O=C(Nc1cnc(Cl)c(Cl)c1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5427600 196602 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 366 1 1 3 4.2 O=C(Nc1cnc(Cl)c(Cl)c1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548722 196768 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 345 2 1 5 3.2 O=C(Nc1nnc(C2CC2)s1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5431825 196768 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 345 2 1 5 3.2 O=C(Nc1nnc(C2CC2)s1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548571 196870 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 339 1 1 5 3.1 O=C(Nc1ccc2nonc2c1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5433744 196870 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 339 1 1 5 3.1 O=C(Nc1ccc2nonc2c1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548655 196961 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 357 1 1 4 3.4 N#Cc1ccc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)nc1Cl nan
CHEMBL5435598 196961 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 357 1 1 4 3.4 N#Cc1ccc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)nc1Cl nan
164548712 197042 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 399 2 1 6 3.1 O=C(Nc1cnc(-n2nccn2)c(Cl)c1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5437369 197042 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 399 2 1 6 3.1 O=C(Nc1cnc(-n2nccn2)c(Cl)c1)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548745 197058 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 303 1 1 5 2.2 Cc1nonc1NC(=O)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
CHEMBL5437775 197058 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 303 1 1 5 2.2 Cc1nonc1NC(=O)N1[C@H]2CC[C@@H]1c1ccnc(F)c1C2 nan
164548570 197178 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 346 2 1 6 2.3 COC(=O)c1cc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)no1 nan
CHEMBL5440522 197178 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assayAntagonist activity at recombinant human GPR65 expressed in human 1321N1 cells assessed as reduction in cAMP level incubated for 30 mins by HTRF assay
ChEMBL 346 2 1 6 2.3 COC(=O)c1cc(NC(=O)N2[C@H]3CC[C@@H]2c2ccnc(F)c2C3)no1 nan
3931 2248 None 39 Human Functional pIC50 = 5.3 5.3 -15848 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 584 17 6 7 4.5 CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)CCNC[C@@H](COc1ccc(cc1)O)O 10.6019/CHEMBL5442687
9829836 2248 None 39 Human Functional pIC50 = 5.3 5.3 -15848 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 584 17 6 7 4.5 CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)CCNC[C@@H](COc1ccc(cc1)O)O 10.6019/CHEMBL5442687
CHEMBL12998 2248 None 39 Human Functional pIC50 = 5.3 5.3 -15848 5
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 584 17 6 7 4.5 CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)CCNC[C@@H](COc1ccc(cc1)O)O 10.6019/CHEMBL5442687
66561564 74688 None 32 Human Functional pIC50 = 5.2 5.2 -301 2
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 509 6 2 4 4.3 CN(C)S(=O)(=O)c1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1 10.6019/CHEMBL5442687
CHEMBL2030155 74688 None 32 Human Functional pIC50 = 5.2 5.2 -301 2
GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65GPCR PRESTO-Tango dose-response in antagonist mode with target: GPR65
ChEMBL 509 6 2 4 4.3 CN(C)S(=O)(=O)c1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1 10.6019/CHEMBL5442687


Get vendors


Ligands (move mouse cursor over ligand name to see structure) Receptor Activity Chemical information
Sel. page Common
name		 GPCRdb
ID		 Reference
ligand		 Vendors

 Species

 Assay
Type		 Activity
Type		 Activity
Relation		 Activity
Value		 p-value
(-log)		 Fold
selectivity		 Tested
GPCRs		 Assay
Description		 Source

 Mol
weight		 Rot
Bonds		 H don

 H acc

 LogP

 Smiles

 DOI